GH
Guardant Health, Inc.NASDAQHealthcare$93.83+2.94%ClosedMarket Cap: $12.31B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-121.56
P/S
12.53
EV/EBITDA
-36.40
DCF Value
$-213.16
FCF Yield
-1.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
64.5%
Operating Margin
-44.5%
Net Margin
-42.4%
ROE
164.9%
ROA
-21.8%
ROIC
-25.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $281.3M | 64.6% | $-120.8M | $-128.5M | $-1.00 | — |
| FY 2025 | $982.0M | 64.5% | $-436.3M | $-416.3M | $-3.32 | — |
| Q3 2025 | $265.2M | 64.7% | $-99.0M | $-92.7M | $-0.74 | — |
| Q2 2025 | $232.1M | 65.0% | $-106.4M | $-99.9M | $-0.80 | — |
| Q1 2025 | $203.5M | 63.3% | $-111.0M | $-95.2M | $-0.77 | — |
| Q4 2024 | $201.8M | 61.6% | $-126.0M | $-111.0M | $-0.90 | — |
| FY 2024 | $739.0M | 60.8% | $-443.6M | $-436.4M | $-3.56 | — |
| Q3 2024 | $191.5M | 61.1% | $-117.3M | $-107.8M | $-0.88 | — |
| Q2 2024 | $177.2M | 59.1% | $-100.6M | $-102.6M | $-0.84 | — |
| Q1 2024 | $168.5M | 61.2% | $-99.7M | $-115.0M | $-0.94 | — |
| Q4 2023 | $155.1M | 152.3% | $-197.5M | $-187.0M | $-1.58 | — |
| FY 2023 | $563.9M | 59.7% | $-564.7M | $-479.4M | $-4.28 | — |